A high-growth, disruptive company with validated soft tissue regeneration products. Supported by innovative digital platforms to address global health issues. Patented fish skin technologies originating from Isafjordur, 20 miles south of the Arctic Circle.

Who We Are

From the town of Isafjordur in northwest Iceland, Kerecis develops, manufactures, and sells patented fish skin soft tissue regeneration products that have regulatory approval in the United States, Europe and several other jurisdictions. We provide our customers with innovative digital tools for managing their business that include the use artificial intelligence (AI) to support insurance billing.

We have regional headquarters in the United States, Iceland, and Germany with around 500 employees including a 250-person US salesforce.

Our Mission

To become the world leader in tissue regeneration by sustainably harnessing nature's own remedies

Our Vision

To extend life by supporting the body's own ability to regenerate

Iceland & The Arctic An island rich in history as a fishing nation, leader in sustainable and responsible fisheries of clean oceans Minimal Environmental impact BioTech facilities run on 100% clean energy and no harsh chemicals Artificial Intelligence Platform Digital platform for increased productivity and superior customer experience

hope and healing

Kerecis



device for tissue regeneration

The Science Behind Kerecis' Fish Skin Technology

Fish skin is homologous to human skin. When applied to the human body, the fish skin provides the ideal environment for the body to recruit its own cells in the regeneration process, remaining in place, and then ultimately converting into living tissue. The fish skin is rich in healthy fatty acids and important proteins, and it is non-allergenic.

true economic value

Because there is no known viral or prion transfer risk between Atlantic cod and humans, the Kerecis fish skin is only gently processed and retains its similarity to human tissue. The gentle processing preserves the skin's original three-dimensional structure, with its inherent natural strength, complexity, and molecules are maintained.

Kerecis has a proven scientific track record, with more than 50 studies using our technology completed to date. These include three large, double-blind, comparative, randomized control trials in which fish skin treatment was demonstrated to be more efficacious than mammalian-based treatments.

Results

2022 fiscal year revenues of \$74m, with 155% YoY growth from 2021 fiscal year revenues

Top-Tier gross margins from technology providing for transforming waste (fish skin) into high-value products in a low-cost process

Financial model is also positively impacted by low-cost logistics as products are shelf-stable for 3 years and can be easily shipped



Kereels



Our Products

Kerecis currently operates and has developed product portfolios based on approved indications in the surgical (SurgiClose/SurgiBind), wound (MariGen), and burn (GraftGuide) segments. The Kerecis products classify as medical devices.

Products are available in sheets that are either solid, fenestrated, or meshed. Micro is intact fish skin that is fragment, and upon rehydration, can be inserted or poured directly into wounds that are complex or irregular.

Kerecis is actively working on expanding its portfolio within the segments it already operates in. New product development projects are underway which not only focus on addressing existing segments, but also new segments as well, such as oral surgery and breast reconstruction.



Digitalization

We provide our customers with tools for managing their business with Kerecis in real time. The Kerecis Current application and artificial intelligence (AI) allows for secure submission and monitoring of insurance verification and billing support cases, as well as provides access to essential clinical literature and the ability to place orders. This way, less time is spent on the phone, faxes, or legacy systems. Likewise our Workspace application gives the sales force real-time access to the company's various tools, increasing productivity.

Our **Sustainability** Commitment ^{to} Sustainability Net Zero **Sustainability** Promoting Emission at Our Core **Ocean Conservation** Kerecis is an active champion of responsible use of Arctic and marine Kerecis is tracking it's greenhouse We are committed to continous gas emission and is working towards improvement of the sustainability of a future goal of Net Zero emission. our value chain and product design. resources and ocean conservation.

Experienced Management Team and Scientific Advisory Board

The Kerecis management team is comprised of seasoned executives with proven track records in building successful medical device businesses, clinical development and the protection of intellectual property. Kerecis founder and CEO, Fertram Sigurjonsson, has held multiple medical and entrepreneurial positions including that at the company Ossur, the world's largest noninvasive orthopedic company. Our board consists of leaders with extensive qualifications from commercial leadership and public service. The company's scientific advisory board is comprised of respected key opinion leaders, including medical doctors and university professors.



Fertram Sigurjonsson Founder & CEO gfs@kerecis.com I believe that Kerecis can help millions of people overcome grave challenges to their health. The need for new therapeutic options is enormous. Multiple clinical trials have proven the efficacy of our products, which are environmentally friendly, harvested from a sustainable stock of wild cod, and is processed with renewable Icelandic energy. This is our contribution to a healthier world population.